Free Trial
OTCMKTS:CEVE

Ceres Ventures (CEVE) Stock Price, News & Analysis

Ceres Ventures logo
$0.0001 0.00 (-50.00%)
As of 05/9/2025 10:24 AM Eastern

About Ceres Ventures Stock (OTCMKTS:CEVE)

Key Stats

Today's Range
$0.0001
$0.0001
50-Day Range
N/A
52-Week Range
$0.0001
$0.0002
Volume
1,004 shs
Average Volume
21 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ceres Ventures, Inc., a development stage company, focuses on the research, development, and commercialization of clean technologies for the remediation of polluted water, soil, and air. Its technologies include BluFlow Nanoparticles, a proprietary system for formulating, producing, and deploying customizable absorbent nanoparticles to specific functionality for contaminant/chemical removal and extraction of valuable elements and compounds from water based solutions; BluFlow Advanced Ultrafiltration Technology, an automated process to recover water from waste or impure streams; and BluFlow Treatment System a water and wastewater treatment solution, which incorporates the BluFlow Nanoparticles and the BluFlow Advanced Ultrafiltration Technology to remove target elements, compounds, and pollutants, as well as purify water that may be suitable for reuse. Ceres Ventures, Inc.'s products are used in water and wastewater treatment and purification, contaminated groundwater treatment, industrial wastewater treatment, and valuable elements and compounds extraction applications. The company was formerly known as PhytoMedical Technologies, Inc. and changed its name to Ceres Ventures, Inc. in November 2011. Ceres Ventures, Inc. was founded in 2010 and is based in New York, New York.

Receive CEVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ceres Ventures and its competitors with MarketBeat's FREE daily newsletter.

CEVE Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Headlines

CEVE Stock Analysis - Frequently Asked Questions

Ceres Ventures' stock was trading at $0.0002 at the beginning of the year. Since then, CEVE stock has decreased by 50.0% and is now trading at $0.0001.
View the best growth stocks for 2025 here
.

Shares of CEVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ceres Ventures investors own include Jiuzi (JZXN), Avalon GloboCare (ALBT), Ainos (AIMD), Aethlon Medical (AEMD), Aditxt (ADTX), Adial Pharmaceuticals (ADIL) and Allarity Therapeutics (ALLR).

Company Calendar

Today
5/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Specialty outpatient clinics, not elsewhere classified
Sub-Industry
Healthcare
Current Symbol
OTCMKTS:CEVE
CIK
N/A
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (OTCMKTS:CEVE) was last updated on 5/10/2025 by MarketBeat.com Staff
From Our Partners